Juul asks court for temporary block on FDA’s ban of its e-cigarettes

Juul asks court for temporary block on FDA’s ban of its e-cigarettes


Juul brand vape cartridges are pictured for sale at a shop in Atlanta, Georgia.

Elijah Nouvelage | Reuters

Juul asked a federal appeals court on Friday to block the Food and Drug Administration’s ban on its e-cigarettes temporarily.

The request came less than a day after the health agency told the company that it had to pull its vaping products off the U.S. market, effective immediately. According to the FDA, Juul’s applications to keep selling its vaping device and menthol- and tobacco-flavored nicotine pods gave insufficient or conflicting data about the potential risks of using the company’s products.

Juul disagreed, saying in a statement that it provided sufficient research and evidence to address the issues raised by the agency. The company’s chief regulatory officer, Joe Murillo, said in a statement on Thursday that Juul is exploring its options, which include appealing the decision or engaging with the FDA.

In a filing with the U.S. Court of Appeals for the D.C. Circuit, Juul asked for an emergency administrative stay until it can file a motion for a stay pending review by noon on Monday. If granted, the company and retailers would be able to keep distributing and selling Juul products until the court reviews the agency’s decision.

“[Juul’s] only prospect for meaningful relief that permits it to continue selling its products is an immediate stay,” the company said in the filing.

Juul claimed that the FDA subjected it to unfair treatment compared with other e-cigarette makers. According to the filing, the agency’s press release announcing its ruling on Juul products was “more strident and threatening” than previous denials.

“FDA’s decision is arbitrary and capricious and lacks substantial evidence, and an immediate administrative stay is critical to protect JLI, its commercial partners, and its customers,” Juul said.

The company also called out the agency for imposing immediate enforcement, rather than instating a transition period, which is typical unless the product poses an immediate risk to consumers.

The FDA declined to comment.



Source

Weight loss drugs could be a gamechanger for women with a common hormonal disorder
Health

Weight loss drugs could be a gamechanger for women with a common hormonal disorder

Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images For well over a decade, Grace Hamilton, 27, experienced hair loss, heavy periods, infrequent menstrual cycles, mental health issues and difficulty losing weight without knowing why. It wasn’t until 2021 when she was diagnosed with […]

Read More
Sarepta shares plunge 40% as future of its gene therapy appears at risk
Health

Sarepta shares plunge 40% as future of its gene therapy appears at risk

Douglas Ingram, president and chief executive officer of Sarepta Therapeutics Inc., during the Forbes Healthcare Summit in New York, US, on Tuesday, Dec. 5, 2023. Michael Nagle | Bloomberg | Getty Images Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy treatment appeared at risk. The […]

Read More
Trump diagnosed with common vein condition after ankle swelling raises concerns
Health

Trump diagnosed with common vein condition after ankle swelling raises concerns

First Lady Melania Trump, President Donald Trump, FIFA President Gianni Infantino and his wife, Leena Al Ashqar, attend the FIFA Club World Cup 2025 final football match between England’s Chelsea and France’s Paris Saint-Germain at MetLife Stadium in East Rutherford, New Jersey, July 13, 2025. Charly Triballeau | AFP | Getty Images President Donald Trump […]

Read More